Molecular mechanisms involved in Weibel-Palade body exocytosis
van Hooren, K.W.E.M.

Citation for published version (APA):
The Epac-Rap1 pathway controls cAMP-mediated exocytosis of Weibel-Palade bodies in endothelial cells

Kathinka W.E.M. van Hooren¹, Ellen L. van Agtmaal¹, Mar Fernandez-Borja², Jan A. van Mourik¹, Jan Voorberg¹ and Ruben Bierings¹

¹From the Departments of Plasma Proteins and
²Molecular Cell Biology, Sanquin Research and Landsteiner Laboratory AMC, Amsterdam, the Netherlands

Abstract

Endothelial cells contain specialized storage organelles called Weibel-Palade bodies (WPBs) that release their content into the vascular lumen in response to specific agonists that raise intracellular Ca^{2+} or cAMP. We have previously shown that cAMP-mediated WPB release is dependent on protein kinase A (PKA) and involves activation of the small GTPase RalA. Here, we have investigated a possible role for another, PKA-independent cAMP-mediated signaling pathway in the regulation of WPB exocytosis, namely the guanine nucleotide exchange factor Epac1 and its substrate, the small GTPase Rap1. Epinephrine stimulation of endothelial cells leads to Rap1 activation in a PKA-independent fashion. siRNA-mediated knockdown of Epac1 abolished epinephrine-induced activation of Rap1 and resulted in decreased epinephrine-induced WPB exocytosis. Downregulation of Rap1 expression and prevention of Rap1-activation through over-expression of Rap1GAP effectively reduced epinephrine- but not thrombin induced WPB exocytosis. Taken together, these data uncover a new Epac-Rap1 dependent pathway by which endothelial cells can regulate WPB exocytosis in response to agonists that signal through cAMP.

Keywords
Exocytosis/Weibel-Palade bodies/Epac/cAMP/Rap1

Abbreviations
6-Bnz-cAMP-AM, N6- Benzoyladenosine- 3’, 5’- cyclic monophosphate, acetoxymethyl ester; AKAP, A-Kinase anchoring protein; DDAVP, desmopressin; EC, Endothelial cells; Epac, exchange protein activated by cAMP; HUVECs, Human Umbilical Vein Endothelial Cells; IBMX, 3-isobutyl-1-methylxanthine; Me-cAMP, 8- (4-Chlorophenylthio)- 2’- O- methyladenosine-3’, 5’- cyclic monophosphate; Me-cAMP-AM, 8- (4-Chlorophenylthio)- 2’- O- methyladenosine- 3’, 5’- cyclic monophosphate, acetoxymethyl ester; MyRIP, Myosin-VIIa- and Rab-Interacting Protein; PKA, Protein Kinase A; SEM, standard error of the mean; VWF, von Willebrand factor; WPB, Weibel-Palade body
Introduction

Vascular endothelial cells provide a dynamic interface between circulating blood and underlying tissues that is critically involved in maintaining vascular integrity and homeostasis. The endothelium provides a surface for adhesion and subsequent extravasation of leukocytes to sites of inflammation. In addition, vascular endothelial cells are involved in the regulation of vascular tone, contribute to neo-vascularisation and mediate the formation of a platelet plug in the event of vascular damage. Rapid recruitment of bio-active components from intracellular storage pools has been shown to contribute to the critical role of endothelial cells in maintaining vascular homeostasis. A significant number of haemostatic components and inflammatory mediators originate from endothelial cell-specific, cigar-shaped organelles called Weibel-Palade bodies (WPBs) [1]. WPBs function as storage vesicles for von Willebrand factor (VWF), a multimeric adhesive glycoprotein crucial for platelet plug formation, the leukocyte receptor P-selectin and a number of bioactive compounds that include the chemoattractants IL-8 and eotaxin-3 [2,3]. Following stimulation with agonists that increase intracellular Ca\(^{2+}\)-levels, such as thrombin or histamine, WPBs fuse with the plasma membrane, thereby releasing their content onto the cellular surface or into the circulation. Also agonists such as epinephrine and vasopressin that raise intracellular levels of cAMP have been shown to promote the release of WPBs [4,5]. The physiological importance of this pathway is illustrated by the rise in VWF levels in patients with von Willebrand’s disease and mild hemophilia A following administration of the vasopressin analogue desmopressin (DDAVP) [6] or epinephrine [7]. In response to cAMP-mediated stimulation a subset of WPBs clusters at the microtubule organizing centre, which involves retrograde transport of vesicles mediated by the dynein-dynactin complex [8,9]. Previous work from our group has indicated that WPB exocytosis in response to cAMP-mediated agonists is partly controlled by a protein kinase A (PKA)-dependent signaling pathway which eventually leads to the activation of RalA, a small GTPase that co-sediments with WPBs in density gradients [10-12]. In its activated form, RalA has been shown to promote exocytosis through interaction with Sec5 and Exo84 [13,14] components of the exocyst complex and by enhancing ARF-dependent phospholipase D1 activity [15]. Consistent with these findings phospholipase D1 has recently been implicated in agonist-induced release of WPBs [16]. Several reports have documented signaling pathways independent of PKA that may be involved in regulation
of cAMP-mediated secretory vesicle release. More specifically, the exchange protein activated by cAMP (Epac) has been implicated in cAMP-mediated vesicle exocytosis [17,18]. In this study we explored a potential role for the cAMP-guanine nucleotide exchange factor Epac and its substrate, Rap1 in the regulation of WPB exocytosis by human primary endothelial cells.

EXPERIMENTAL PROCEDURES

Reagents and antibodies
Culture media, trypsin, penicillin, and streptomycin were from Invitrogen (Breda, the Netherlands). EGM-2 was from Lonza Verviers (Verviers, Belgium). Epinephrine, thrombin, forskolin, 3-isobutyl-1-methylxanthine (IBMX), anti-Myc mouse monoclonal antibody (9E10) and anti-α-tubulin mouse monoclonal antibody (DM1A) were from Sigma-Aldrich Chemie (Steinheim, Germany). Phalloidin-Alexa488 was from Molecular Probes (Leiden, The Netherlands). The Epac-specific cAMP-analogue 8-pCPT-2’-O-Me-cAMP–AM (Me-cAMP-AM) [19] and the PKA-specific cAMP-analogue 6-Bnz-cAMP-AM [20] were from Biolog (Bremen, Germany). Glutathione Sepharose 4B was from GE Healthcare Europe GmbH (Diegem, Belgium). Anti-Rap1 rabbit polyclonal antibody (sc-121) and anti-β-catenin rabbit polyclonal antibody (sc-7199) were from Santa Cruz Biotechnology (Santa Cruz, USA). Anti-VWF mouse monoclonal antibody CLB-RAg20 has been described previously [21]. The Epac1 mouse monoclonal antibody 5D3 [22] was a kind gift from Dr. J.L. Bos. Alexa 488- and Alexa 633-conjugated goat anti-mouse IgG, Alexa 568- goat anti-rabbit IgG secondary antibodies and Alexa 488-Phalloidin were from Invitrogen (Breda, the Netherlands). Chemiluminescence blotting substrate and Complete Protease Inhibitor Cocktail Tablets were from Roche Diagnostics (Mannheim, Germany). All chemicals used were of analytical grade. The enzyme-linked immunosorbent assay (ELISA) for VWF and VWF propeptide have been described previously [23].

Cell culture
Human umbilical vein endothelial cells (HUVECs) were isolated from umbilical veins and cultured in EGM-2 medium. Stimulation of endothelial cells with thrombin or epinephrine was performed in the following manner: HUVECs, grown in 6-well plates, were washed two times with serum-free medium (SF medium: 50% M199; 50% RPMI1640; 0.3 mg/ml L-glutamine; 100 units/ml penicillin; 100 mg/l streptomycin). After washing, cells were
pre-incubated with SF-medium for 1 hour. At the beginning of stimulation, the pre-incubation medium was replaced by SF medium containing either 1 unit/ml thrombin; a mix of 10 μM epinephrine and 100 μM IBMX; a mix of 10 μM forskolin and 100 μM IBMX; 1 μM Me-cAMP-AM or 1 μM 6-Bnz-cAMP-AM.

**siRNA**
All siRNAs were purchased from Dharmacon (Thermo Fisher Scientific Dharmacon Products, Lafayette, Colorado, USA). For siRNA-mediated knock-down of Epac1, siGENOME SMARTpool M-007676-01 RapGEF3 was used. Individual siRNA J-007676-05 (target sequence CGUGGAACUCAUGAGAUG) derived of the ON-TARGETplus Set of 4 Upgrade, human RapGEF3 (LU-007676) was used to verify the results obtained with the siGENOME Smartpool of RAPGEF3.

For siRNA-mediated knock-down of Rap1, siGENOME SMARTpool M-003623-02 (human Rap1a) and siGENOME SMARTpool M-010364-03 (human Rap1b) were used. SiGENOME Non-Targeting siRNA Pool #1 (D-001206-13-05) was used as a control in these experiments. SiRNA (20 pmol per well of a 6-well plate) was delivered to HUVECs by transfection using Interferin (PolyPlus, Westburg, Leusden, the Netherlands) according to the manufacturer’s instructions. Transfected HUVECs were grown on fibronectin-coated glass coverslips for 72 hours before stimulation.

**Production of DNA constructs and viral vectors**
The full-length Rap1GAP cDNA clone 5767775 was obtained from Open Biosystems (Thermo Fisher Scientific, Open Biosystems Products, Huntsville, Alabama, USA). A myc-tag was inserted at the amino-terminus of Rap1GAP using the following oligonucleotide primers: (fw1) AATATGGGACGACAAGCTGATCTCCGAGGAGGACCTGATTGAGAAGATGCAGGGAAGCAGGAT, (Rev1) AATGAATTCCCTGCAGGCTAACAGCCCAGCTGGGGCATGTGCTGCT. A second PCR reaction with forward primer (Fw2) AATATGGGACGACAAGCTGATCTCCGAGGAGGACCTGATTGAGAAGATGCAGGGAAGCAGGAT and rev1 was used to introduce Nhel and Sbf1 restriction sites that facilitated cloning in the lentiviral vector pLV-CMV [24]. The final pLV-CMV-myc-Rap1GAP construct was checked by sequencing.

The lentiviral (LV) packaging system consists of three constructs encoding gag/pol (pMDL.RRE), vesicular stomatitis virus glycoprotein envelope (pCMV-VSV-G) and rev (pRSV-Rev) [25]. Lentivirus was prepared essentially as described previously [21].
Rap1 activation assays
The Ras binding domain (RBD) of RalGDS fused to a GST tag was expressed in IPTG-induced bacteria as described previously [26]. Purified GST-RBD (100 µg/sample) was pre-coupled to 30 µl/sample of Glutathione Sepharose 4B for 1 hour at 4°C. The pre-coupled Glutathione Sepharose was then washed 3 times with lysis buffer containing 15% (v/v) glycerol, 1% NP-40, 50 mM Tris-HCl (pH 7.5), 200 mM NaCl, 2.5 mM MgCl₂, 10 mM benzamidine, 100 nM aprotinin, supplemented with 1 protease inhibitor tablet per 50 ml. Following stimulation, cells grown in 6-wells plates, were lysed in 400 µl lysis buffer. The activated, GTP-bound form of Rap1 was then isolated from cell lysates by incubation of 300 µl lysate with GST-RBD pre-coupled Glutathione Sepharose for 1 hour at 4°C. Finally, the Sepharose beads were washed 4 times with lysis buffer, bound proteins were resuspended in Laemmlli sample buffer. Proteins were run on a 12.5 % SDS-PAGE gel and analysed by Western blotting employing an anti-Rap1 polyclonal antibody.

Results
Epac and VWF secretion
Exocytosis of WPBs occurs following triggering of G coupled proteins of the Gₛ subtype which elevate intracellular cAMP levels and promote PKA-dependent activation of RalA [4,5,12]. Inhibition of PKA returns epinephrine-induced activation of Ral to basal levels and thereby abolishes VWF secretion [12]. Epac, the exchange protein activated by cAMP for the small GTPases Rap1 and Rap2, is involved in regulation of endothelial barrier function [27-29] endothelial cell adhesion [30] but also regulated secretion of insulin in pancreatic beta-cells [31]. Endothelial cells selectively express Epac1 but not Epac2 [28,29]. It has been previously shown that the Epac-specific cAMP analogue 8-pCPT-2’-O-Me-cAMP promotes exocytosis of WPBs [9,32]. To determine whether Epac plays a role in cAMP-mediated WPB exocytosis, we first confirmed that 1 µM of 8-pCPT-2’-O-Me-cAMP–AM (Me-cAMP-AM) promotes release of VWF (Figure 1A). Similarly, the PKA-specific agonist 6-Bnz-cAMP-AM also induced release of VWF at a concentration of 1 µM, however Me-cAMP-AM and 6-Bnz-cAMP-AM are less potent in the induction of VWF secretion when compared to 10 µM epinephrine and 10 µM forskolin both supplemented with 100 µM of the phosphodiesterase inhibitor IBMX (Figure 1A). When Me-cAMP-AM and 6-Bnz-cAMP-AM are used in combination at a concentration of 1 µM, an additive effect can be observed that is illustrated
by a statistically significant increase of VWF secretion compared to when the stimuli are used individually, suggesting a contribution of both Epac and PKA pathways in WPB release. However, the combination of Me-cAMP-AM and 6-Bnz-cAMP-AM did not reach the level of VWF secretion induced by Epinephrine + IBMX (Supplemental Figure S1A).

To further substantiate the involvement of Epac in the regulated exocytosis of WPBs in endothelial cells we used siRNA-mediated silencing of Epac1 (Figure 1B), followed by stimulation with different agonists. Depletion of Epac1 did not notably alter the number or distribution of WPBs (Supplemental Figure S2). In the absence of Epac1, epinephrine and forskolin-induced release of WPBs was decreased as evidenced by the decline in released VWF (Figure 1C). In contrast, thrombin-induced release of WPBs, which is not mediated by cAMP but uses Ca$^{2+}$ as second messenger, was not affected by knock-down of Epac1 (Figure 1C). As expected Me-cAMP-AM-induced VWF release was also dependent on Epac1 whereas 6-Bnz-cAMP-AM-induced VWF release was not (Figure 1C). Stimulation with these agonist is accompanied by changes in cytoskeletal organization: Epinephrine and Me-cAMP-AM led to an increase in cortical actin in an Epac1-dependent manner, in line with earlier reports [29], whereas thrombin-induced the formation of stress fibers independent of Epac1 (Supplemental Figure S3).

A pool of four siRNAs targeting Epac1 was used for these experiments; assessment of an individual siRNA targeting Epac1 yielded similar results (Supplemental Figure S1B). Together, our findings show that epinephrine and forskolin-induced release of WPBs requires Epac1.

**Rap1 activation**

Activation of the small GTPase Rap1 by Me-cAMP and forskolin in HUVEC proceeds in an Epac-dependent manner [27,28]. To confirm that agonists are able to activate the Epac/Rap1 pathway we performed Rap1 activity assays. Similar as when challenged with Me-cAMP-AM (Figure 2A) or the cAMP-elevating compound forskolin (not shown), endothelial cells activate Rap1 when stimulated with epinephrine and IBMX (Figure 2B); after 5 minutes a sustained increase in the amount of Rap1-GTP was observed. These results indicate that triggering of WPB exocytosis with the cAMP-elevating agonist epinephrine is accompanied by the activation of Rap1. As in the original study of Vischer et al. [5], we routinely added the phosphodiesterase inhibitor IBMX to prevent degradation of cAMP to potentiate cAMP-mediated processes [12]. IBMX has been reported to increase intracellular cAMP in endothelial cells, and it has been shown to increase the amount of active Rap1 in several
cellular systems. To test whether the cAMP rise within endothelial cells induced by IBMX alone would suffice for WPB release, we measured VWF release from endothelial cells treated for 45 minutes with either 100 μM IBMX or 10 μM epinephrine, or both. Only when challenged with epinephrine in combination with IBMX were we able to detect a significant increase in VWF secretion (Figure 2E). In agreement with previous findings [5], IBMX on its own only induced a modest increase in WPB release, despite its ability to activate Rap1 activation (Figure 2C). As reported previously, incubation with epinephrine alone resulted in only a modest increase in VWF release (Figure 2E) [5]. Also under these conditions an increase in Rap1 activation was observed (Figure 2C). Following incubation with thrombin (1 unit/ml)
A sharp but transient increase in the amount of active Rap1 (Figure 2D) was observed, confirming earlier findings by Cullere et al. [27]. The amount of active Rap1 was maximal after 2 min of thrombin stimulation and decreased to background levels after 10 min. Currently the identity of the exchange factor responsible for the thrombin-induced Rap1 activation in endothelial cells is unclear; however the Ca\(^{2+}\) and diacylglycerol (DAG) activated exchange factor for Rap1, CalDAG-GEFI, has been shown to induce Rap1 activation in platelets in response to thrombin [33]. This raises the possibility that guanine exchange factors of the CalDAG-GEF family are involved in thrombin-induced Rap1 activation in endothelial cells. These findings show that both epinephrine- and thrombin-induced exocytosis of WPB coincides with the activation of the small GTPase Rap1. Remarkably, the kinetics of Rap1 activation in response to thrombin and epinephrine are very similar to that observed for the activation of the small GTPase RaLA [12,34], suggesting that these two GTPases are activated in a coordinated fashion.

![Figure 2. Stimulus-induced WPB exocytosis is accompanied by activation of the small GTPase Rap1.](image)

Cells were pre-incubated with SF-medium for 1 hour. Subsequently, cells were stimulated with 1 \(\mu\)M Me-cAMP-AM (A), 10 \(\mu\)M epinephrine and 100 \(\mu\)M IBMX (B), 10 \(\mu\)M epinephrine alone, 10 \(\mu\)M epinephrine and 100 \(\mu\)M IBMX or 100 \(\mu\)M IBMX alone (C) or 1 unit/ml thrombin (D) for the indicated periods. Activation of Rap1 in HUVECs was determined using a Rap1-GTP specific pull-down. Western blots of activated Rap1 demonstrate the activation of Rap1 by cAMP- and Ca\(^{2+}\)-mediated agonists. The amount of total Rap1 shown in the lower panels is used as loading control. (E) HUVEC were pre-stimulated with SF-medium for 1 hour, and then treated for 45 minutes with SF-medium (-), 10 \(\mu\)M epinephrine (Epi), 100 \(\mu\)M IBMX (IBMX) or 10 \(\mu\)M epinephrine and 100 \(\mu\)M IBMX together (Epi IBMX). VWF secretion in the medium was assessed by VWF ELISA. (\(n=6\); ***, \(P<0.001\); *, \(P<0.05\) by 1-way ANOVA followed by Dunnett post-hoc test.) Error bars show SEM.
Subsequently, we addressed whether siRNA-mediated knockdown of Epac1 abolished epinephrine-induced activation of Rap1. In agreement with previous findings [28], knockdown of Epac1 did abolish the activation of the small GTPase Rap1 by epinephrine, but not by thrombin (Figure 3). These findings confirm that Rap1 is activated in an Epac-dependent manner in endothelial cells upon stimulation with cAMP- but not Ca\textsuperscript{2+}-elevating agonists [27,28,35].

![Figure 3. Impaired epinephrine-stimulated Rap1 activation in endothelial cells after downregulation of Epac1.](image)

**Figure 3. Impaired epinephrine-stimulated Rap1 activation in endothelial cells after downregulation of Epac1.** HUVECs treated with Epac1 siRNA (siEpac1) or control siRNA (siCTRL) were pre-incubated with SF-medium for 1 hour. Subsequently, cells were stimulated with 10 \( \mu \text{M} \) epinephrine and 100 \( \mu \text{M} \) IBMX (Epi) or 1 unit/ml thrombin (Thr) for the indicated minutes. Activation of Rap1 in HUVECs was determined using a Rap1-GTP specific pull-down. Western blots of Rap1-GTP illustrate the inability of Epac1 downregulated endothelial cells to activate Rap1 in response to epinephrine, while thrombin-induced Rap1 activation remains unaffected. The total amount of Rap1 shown in the middle panel is used as loading control.

**Rap1 activation and VWF release**

To further establish whether the Epac-Rap1 pathway is involved in the regulation of WPB exocytosis by cAMP-raising agonist, we used two strategies to downregulate endogenous Rap1 activity as follows: the siRNA-mediated knockdown of Rap1a and Rap1b and the ectopic expression of Rap1GAP. The Rap1 antibody used in this study cannot discriminate between Rap1a and Rap1b. Silencing of either Rap1a or Rap1b did not result in a complete lack of Rap1 expression (supplemental Figure S4) suggesting that both isoforms are expressed in endothelial cells. Co-administration of Rap1a and Rap1b siRNA resulted in efficient silencing of Rap1 (Figure 4A; supplemental Figure S4). Silencing of Rap1 did not affect steady state WPB numbers or distribution.
and also its effects on cytoskeletal remodelling were comparable to down-regulation of Epac1; cytoskeletal remodelling induced by epinephrine or Me-cAMP-AM was abrogated; however, actin stress fiber formation induced by thrombin was unaffected (supplemental Figure S3). Under these conditions both epinephrine- and forskolin-induced releases of VWF were strongly reduced, but thrombin-induced release was not affected (Figure 4B). As expected, Me-cAMP-AM-induced VWF release was completely abolished, whereas 6-Bnz-cAMP-AM-induced release was not affected (Figure 4B). This indicates that Rap1 is required for epinephrine-induced release of WPBs from endothelial cells. It also suggests that the role of Epac in WPB exocytosis depends on its ability to catalyze the GDP/GTP-exchange of Rap1.

Figure 4. Downregulation of Rap1 expression inhibits epinephrine-induced WPB release. (A) HUVECs were transfected with a control siRNA SMARTpool (siCTRL) or a siRNA SMARTpool targeting Rap1a and Rap1b (siRap1a + siRap1b). Western blot analysis 72 hours post transfection showed downregulation of Rap1 expression. Levels of α-tubulin are shown as a protein loading control. (B) Control siRNA and Rap1 siRNA (siRap1a + siRap1b) treated HUVECs were incubated for 60 minutes with SF medium (-), supplemented with 1 μM Me-cAMP-AM (Me), 1 μM 6-Bnz-cAMP-AM (Bnz), 10 μM epinephrine and 100 μM IBMX (Epi), 10 μM forskolin and 100 μM IBMX (Fsk) or 1 unit/ml thrombin (Thr). The amount of VWF released is expressed as percentage relative to the amount of VWF released in the absence of a stimulus. (n=3; *** P<0.001; n.s., non significant; by 2-way ANOVA followed by Bonferroni post-hoc test for selected comparison.) Error bars show SEM.

Ectopic expression of myc-tagged Rap1GAP was used to explore the potential role of Rap1 activation in regulated exocytosis of WPBs. Rap1GAP is a GTPase activating protein specific for Rap1 but with no GAP activity towards related GTPases such as Rap2 or Ras [36]. Earlier reports have shown that the amount of active Rap1 was strongly reduced in cells overexpressing Rap1GAP [37]. HUVECs were transduced with lentiviruses encoding GFP, as negative control, or myc-Rap1GAP. Confluent monolayers of HUVECs
were stimulated with agonists, and the activation of Rap1 was determined. Overexpression of Rap1GAP prevented both thrombin- and epinephrine-induced activation of Rap1, whereas overexpression of GFP did not affect Rap1 activation (Figure 5A). This shows that Rap1GAP overexpression is an efficient method to inhibit endogenous Rap1 activity in HUVECs. We also measured VWF release in endothelial cells overexpressing Rap1GAP. A strong decline in epinephrine- and forskolin-induced release of VWF was observed in cells overexpressing Rap1GAP, whereas thrombin-induced release of VWF was not affected (Figure 5B). As expected expression of GFP did not prevent epinephrine- or forskolin-induced VWF release. Also, Me-cAMP-AM-induced VWF release was abolished by Rap1GAP, whereas 6-Bnz-cAMP-AM-induced release was not affected (Figure 5B). These findings show that activation of Rap1 is required for cAMP-dependent exocytosis of WPBs.

Figure 5. Activation of Rap1 is crucial for epinephrine-induced WPB release. HUVECs were transduced with GFP (negative control) or Rap1GAP carrying a myc-tag (myc-Rap1GAP) and were grown for 72 hours. (A) Cells were incubated with 1 unit/ml thrombin (Thr), 10 μM epinephrine and 100 μM IBMX (Epi) or 1 μM Me-cAMP-AM (Me) for the indicated minutes. Activation of Rap1 in HUVECs was determined using a Rap1-GTP specific pull-down. The total amount of Rap1 shown in the second panels is used as loading control. GFP and myc-Rap1GAP expression are shown in the lower panels. (B) Transduced HUVECs were incubated with SF medium (-), supplemented with 1 μM Me-cAMP-AM (Me), 1 μM 6-Bnz-cAMP-AM (Bnz), 10 μM epinephrine and 100 μM IBMX (Epi), 10 μM forskolin and 100 μM IBMX (Fsk) or 1 unit/ml thrombin (Thr). After 60 minutes the medium was collected and VWF secretion was measured by ELISA. VWF secretion is expressed in percentages relative to the amount of VWF released without stimulation (n=3; ***, P<0.001; n.s., non significant; by 2-way ANOVA followed by Bonferroni post-hoc test for selected comparison.) Error bars show SEM.
Discussion

Agonist-induced release of WPBs allows for the rapid mobilization of adhesion molecules, chemokines, and vaso-active compounds from endothelial cells [3]. At present two intracellular signaling pathways have been described that promote release of WPBs. Agonists like histamine and thrombin mediate WPB release by raising intracellular Ca^{2+} levels, whereas cAMP-dependent signaling pathways control epinephrine- and vasopressine-induced release of WPBs. Previous studies have supported the concept that both signaling pathways converge at the level of the guanine exchange factor RalGDS [11]. Subsequent activation of the small GTPase Ral promotes assembly of the exocyst complex and mediates phospholipase D1-facilitated fusion of WPBs with the plasma membrane [16,34]. In this study, we show that Epac1, through the activation of the small GTPase Rap1, is crucial for epinephrine- but not for thrombin-induced release of WPBs. In agreement with previous findings we observed that Rap1 is activated in an Epac-independent manner following stimulation of endothelial cells with thrombin. Overexpression of Rap1GAP does not interfere with thrombin-induced release of WPBs indicating that activation of Rap1 is not critical for Ca^{2+}-mediated WPB release. Thrombin is a prothrombotic and pro-inflammatory agonist that elicits a rapid activation of Ral [12,34]. We anticipate that the massive activation of Ral and the rise of intracellular Ca^{2+} by Ca^{2+}-mediated agonists such as thrombin may be sufficient to promote WPB exocytosis. In contrast, the slow but sustained activation of Ral by cAMP-raising agonists like epinephrine may require concomitant activation of Rap1 to induce WPB release. Previously, we have shown that the Epac-specific CAMP-analogue 8-CPT-2’-O-Me-cAMP can promote release of WPBs independent of Ral activation [12]. This observation suggests that apart from Rap1 other downstream effectors of Epac may also contribute to WPB exocytosis. In response to G-protein coupled receptor activation, Epac also catalyzes the activation of the small GTPase R-Ras, which in turn can also promote phospholipase D activity [38]. Under these conditions WPB exocytosis may occur in the absence of detectable Ral activation.

In earlier reports we and others have shown that PKA is involved in cAMP-mediated release of WPBs, through the exchange factor RalGDS [4,11,12]. From the findings documented in the current study, it now appears that activation of Rap1 through Epac is also required for this process. Apparently, two parallel signaling pathways are needed for cAMP-mediated exocytosis of WPBs in endothelial cells. Epac1 and the holoenzyme PKA have a similar affinity for cAMP allowing them to respond to similar concentrations of
intracellular cAMP [39]. At present limited knowledge is available how activation of Epac and PKA is coordinated in endothelial cells. Integration of cAMP effector pathways by protein kinase A anchoring proteins (AKAPs) has been documented previously in different biological systems [40]. Phosphodiesterases have also been shown to interact with different members of the AKAP family allowing for further fine-tuning of cAMP-dependent signaling. Interestingly, Epac1 has been demonstrated to interact with and regulate the activity of mAKAP-bound PDE4D3 in cardiomyocytes [41]. In endothelial cells Epac1 binds to AKAP9, thereby integrating microtubule dynamics and barrier function [42]. Recently, a study by Nightingale and co-workers [43] has implicated the Rab27a effector myosin-VIIa- and Rab-interacting protein (MyRIP) in WPB release. From their study, it appears that the Rab27a-MyRIP complex acts as a negative regulator of exocytosis, probably by trapping Rab27a-coated WPBs in the actin filaments via the actin motor protein myosin-Va [44]. As was also suggested by Nightingale et al. [43], an additional role may lie in its capacities to act as an AKAP and interact with Sec6 and Sec8, bringing together PKA with members of the exocyst complex [45]. We speculate that this would facilitate the assembly of a signaling module on WPBs that focuses the cAMP-Epac/PKA pathways to their downstream effectors in secretory granule exocytosis. Based on these findings we anticipate that AKAP scaffolds are also involved in regulation of cAMP-mediated WPB release in endothelial cells.

In this study we show that activation of Rap1 is essential for cAMP-mediated release of WPBs. Rap1 has been implicated in exocytosis of secretory granules in a number of cellular systems [46]. Multiple down-stream effectors of Rap1 have been identified [47]. Binding of Rap1 to the Rac1 guanine exchange factors Vav2 or Tiam promotes cell spreading [48]. Rac1 has also been identified as a downstream effector of Epac/Rap1 in the release of amyloid precursor protein from transfected CHO cells [49]. Subsequent studies revealed that Rap1 interacts with the Rac1-specific guanine exchange factor STEF in this system [50]. Interestingly, Rac1 has been implicated in release of WPBs [48]. These observations raise the possibility that Rap1 controls the activation of Rac1 thereby coordinating cytoskeletal rearrangements that facilitate WPB exocytosis.

In summary, the data presented in this work have uncovered a novel pathway by which endothelial cells can regulate WPB exocytosis in response to agonists that signal through cAMP (Figure 6). Our findings implicate Epac1 as an important regulator of β2-adrenergic and vasopressin-2 receptor-
mediated WPB exocytosis, and suggest that Epac1 may perform a prominent role in the systemic regulation of VWF levels in plasma.

Figure 6. Signaling pathways that regulate cAMP-mediated WPB exocytosis. Stimulation of the β2-adrenergic receptor (β2AR) by epinephrine stimulates cAMP production by Gs-activated adenylate cyclase (AC). Emanating from cAMP, a PKA-dependent pathway induces the activation of the small GTPase RalA by RalGDS, while simultaneously Epac1 activates Rap1. Activated RalA promotes PLD1 activity as well as assembly of the exocyst complex. In parallel, activated Rap1 facilitates WPB exocytosis, possibly by inducing cytoskeletal rearrangements.

Acknowledgments

We thank Dr. J.L. Bos for providing 5D3 antibody and Dr. Matthijs R.H. Kooistra and Drs. Anouk van Veen for helpful discussions.

This study was supported by a grant from the Netherlands Heart Foundation (grant 2002.B187), a grant from the Landsteiner Foundation for Blood Transfusion Research (LSBR 08.19) and a grant from the Dutch Organization for Scientific Research (NWO TOP-grant 91209006).
Chapter 2

References

15. Vitale, N., Mawet, J., Camonis, J., Regazzi, R., Bader, M.-F., and Chasserot-Golaz,
Epac Controls WPB Exocytosis


Sehrawat, S., Cullere, X., Patel, S., Italiano, J., Jr., and Mayadas, T. N. (2008) Role of
Epac1, an exchange factor for Rap GTPases, in endothelial microtubule dynamics and barrier function. Mol. Biol. Cell 19, 1261-1270


getting to the heart of the matter. Trends Mol. Med. 12, 317-323


Figure S1. Involvement of Epac in cAMP-mediated WPB release. (A) HUVECs were incubated with SF medium (-), supplemented with 1 µM Me-cAMP-AM (Me), 1 µM 6-Bnz-cAMP-AM (Bnz), 1 µM Me-cAMP-AM + 1 µM 6-Bnz-cAMP-AM (Me+Bnz) or 10 µM epinephrine and 100 µM IBMX (Epi). After 60 minutes the amount of VWF secreted in the medium was measured by ELISA. Basal VWF secretion (unstimulated) was set to 100%. (n=6, ***, P<0.001, 1-way ANOVA followed by Bonferroni post-hoc test.) Error bars show SEM. (B) HUVECs were transfected with a control siRNA (siCTRL) or a single siRNA targeting Epac1 (siJ-007676). Western blot analysis 72 hours post transfection showed downregulation of Epac1 expression. Levels of α-tubulin are shown as a protein loading control. (B) Control siRNA (siCTRL) and single Epac1 siRNA (siJ-007676) treated HUVECs were incubated for 60 minutes with 1 unit/ml thrombin, 10 µM forskolin and 100 µM IBMX, 10 µM epinephrine and 100 µM IBMX, 1 µM Me-cAMP-AM, 1 µM 6-Bnz-cAMP-AM or SF-medium alone (unstimulated). The amount of VWF secreted in the medium. Unstimulated VWF secretion (unstimulated) is set to 100%. (n=3; ***, P<0.001; *, P<0.05; n.s., non significant; by 2-way ANOVA followed by Bonferroni post-hoc test for selected comparison.) Error bars show SEM.
Figure S2. Number and distribution of WPBs at steady state is independent of Epac1 or Rap1. Endothelial cells were treated with pools of siCTRL, siEpac1 and siRap1 oligos as described and were cultured for 72 hours. Cells were paraformaldehyde fixed and stained for β-catenin (red) and VWF (green). (A) Representative low power images are shown. Scale bar represents 50 µm. (B) For the conditions described above, numbers of WPBs per cell were counted as described [11] (n=10). No significant differences in numbers of WPBs per cell were observed by 1-way ANOVA. Error bars show SEM.
Figure S3. Cytoskeletal reorganization in response to Me-cAMP-AM or epinephrine is dependent on Epac and Rap1. Endothelial cells were treated with pools of siCTRL, siEpac1 and siRap1 oligos as described and were cultured for 72 hours. Cells were paraformaldehyde fixed and stained for β-catenin (red) and actin with Alexa 488-phalloidin (green). (A) Representative low power images are shown. Scale bar represents 50 µm. (B) For the conditions described above, the degree of colocalization (colocalization coefficient) between actin and β-catenin in 5 fields of view was determined using the Zen software package (Carl Zeiss B.V., Sliedrecht, Netherlands). Shown are the results of one experiment, representative of three independent experiments. ***, P<0.001 by 2-way ANOVA followed by Bonferroni post-hoc test for selected comparison. Error bars show SEM.

** Please see also Appendix A of this thesis.
Figure S4. **Downregulation of Rap1 in endothelial cells.** Huvecs were transfected with a control siRNA SMARTpool (siCTRL) or siRNA SMARTpool targeting Rap1a, Rap1b or a mixture of SMARTpool siRNA targeting Rap1a and Rap1b. Western blot analysis 72 hours post transfection showed downregulation of Rap1 expression. The shorter and longer exposure times illustrate the partial effect of siRap1a and siRap1b. Levels of α-tubulin are shown as a protein loading control.